Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I Study of ICP-B794 in Advanced Solid Tumors
NCT07136558Phase 1Not yet recruiting
- Sponsor
- InnoCare Pharma
- Start
- Aug 2025
- Primary completion
- Jun 2029
- Modality
- Antibody-Drug Conjugates (ADCs), Engineered Antibody Formats, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of ICP-B794 in solid tumor (advanced stage), sponsored by InnoCare Pharma. Primary endpoints: Incidence, character, and severity of adverse events (AEs) up to 2 years, Dose-limiting toxicities up to 2 years and 2 more. Planned start Aug 2025; status: not yet recruiting.
02
Drugs
ICP-B794
03
Conditions
solid tumor (advanced stage)
Beyond the preview
Go deeper on NCT07136558.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07136558.